Skip to main content

Advertisement

SpringerLink
Log in

Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Acute myeloid leukemia (AML) relapse after allogeneic stem cell transplant (alloSCT) remains a major therapeutic challenge. While patients with longer remission after initial alloSCT are recommended to receive cell therapy (CT) such as 2ndalloSCT or donor lymphocyte infusion (DLI), survival for patients who relapse within 6 months of alloSCT has been dismal. We evaluated the outcomes of AML relapse after alloSCT to assess the impact of different treatments on long-term survival. One hundred and seventy-two patients with AML underwent alloSCT at the Penn State Cancer Institute from January 2014 to August 2019. Sixty-nine patients relapsed (median age, 60 years; range, 10–75). Of these, 4 patients underwent 2ndalloSCT, and 26 received DLI. One-year overall survival (OS) in all cases was 20.3% (95% CI: 11.8–30.4%). Patients with ECOG performance status (PS) 0–2 at relapse showed a better 1-year OS than those with PS 3–4. Median OS for patients who received chemotherapy only or chemotherapy with CT was 74 or 173.5 days, respectively (p < 0.001). Relapsed patients receiving conventional re-induction chemotherapy were categorized as the high-intensity chemotherapy (H) group, while those receiving treatments such as hypomethylating agents or targeted agents were categorized as the low-intensity chemotherapy (L) group. The H group showed a better 1-year OS compared with the L group. Patients who received H + CT showed a better 1-year OS of 52.9% than the other 3 groups (p < 0.001). Even for patients with post-alloSCT remission duration of less than 6 months, the statistical significance was preserved. Factors including age, donor source at 1stalloSCT, time to relapse, blast counts, PS at relapse, and treatment type after post-alloSCT relapse were used for a multivariate analysis, and matched or mismatched related donor and H + CT after alloSCT were identified as independent factors associated with OS. These findings support the use of H + CT as the treatment option of choice for AML patients who relapse after alloSCT when feasible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Milligan DW, Grimwade D, Cullis JO et al (2006) Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 135(4):450–474

    Article  CAS  Google Scholar 

  2. Bejanyan N, Weisdorf DJ, Logan BR et al (2015) Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant 21(3):454–459

    Article  Google Scholar 

  3. Barrett AJ, Battiwalla M (2010) Relapse after allogeneic stem cell transplantation. Expert Rev Hematol 3(4):429–441

    Article  Google Scholar 

  4. Schroeder T, Rautenberg C, Krüger W et al (2018) Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol 97(2):335–342

    Article  CAS  Google Scholar 

  5. Schmid C, Labopin M, Nagler A et al (2007) Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 25(31):4938–4945

    Article  CAS  Google Scholar 

  6. Orti G, Barba P, Fox L et al (2017) Donor lymphocyte infusions in AML and MDS: enhancing the graft-versus-leukemia effect. Exp Hematol 48:1–11

    Article  CAS  Google Scholar 

  7. Savani BN, Mielke S, Reddy N et al (2009) Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant 44(12):769–777

    Article  CAS  Google Scholar 

  8. Döhner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447

    Article  Google Scholar 

  9. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458

    Article  CAS  Google Scholar 

  10. Ertz-Archambault N, Kosiorek H, Slack JL et al (2017) Cytogenetic evolution in myeloid neoplasms at relapse after allogeneic hematopoietic cell transplantation: association with previous chemotherapy and effect on survival. Biol Blood Marrow Transplant 23(5):782–789

    Article  CAS  Google Scholar 

  11. Kharfan-Dabaja MA, Labopin M, Polge E et al (2018) Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol 4(9):1245–1253

    Article  Google Scholar 

  12. Kurosawa S, Fukuda T, Tajima K et al (2009) Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation. Am J Hematol 84(12):815–820

    Article  Google Scholar 

  13. Schmid C, Labopin M, Nagler A et al (2012) Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 119(6):1599–1606

    Article  CAS  Google Scholar 

  14. Imus PH, Blackford AL, Bettinotti M et al (2017) Major histocompatibility mismatch and donor choice for second allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 23(11):1887–1894

    Article  Google Scholar 

  15. Ruutu T, de Wreede LC, van Biezen A et al (2015) Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant 50(12):1542–1550

    Article  CAS  Google Scholar 

  16. Schmid C, Labopin M, Schaap N et al (2019) Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. Br J Haematol 184(5):782–787

    Article  CAS  Google Scholar 

  17. Choi SJ, Lee JH, Kim S et al (2004) Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 18(11):1789–1797

    Article  CAS  Google Scholar 

  18. Takami A, Okumura H, Yamazaki H et al (2005) Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation. Int J Hematol 82(5):449–455

    Article  CAS  Google Scholar 

  19. Eapen M, Giralt SA, Horowitz MM et al (2004) Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 34(8):721–727

    Article  CAS  Google Scholar 

  20. Levine JE, Braun T, Penza SL et al (2002) Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 20(2):405–412

    Article  CAS  Google Scholar 

  21. Craddock C, Jilani N, Siddique S et al (2016) Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial. Biol Blood Marrow Transplant 22(2):385–390

    Article  CAS  Google Scholar 

  22. Ghobadi A, Choi J, Fiala MA et al (2016) Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. Leuk Res 49:1–6

    Article  CAS  Google Scholar 

  23. Schroeder T, Rautenberg C, Haas R et al (2018) Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol 107(2):138–150

    Article  CAS  Google Scholar 

  24. Stahl M, DeVeaux M, Montesinos P et al (2018) Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv 2(8):923–932

    Article  CAS  Google Scholar 

  25. Motabi IH, Ghobadi A, Liu J et al (2016) Chemotherapy versus hypomethylating agents for the treatment of relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplant. Biol Blood Marrow Transplant 22(7):1324–1329

    Article  CAS  Google Scholar 

  26. Rashidi A, Weisdorf DJ, Bejanyan N (2018) Treatment of relapsed/refractory acute myeloid leukaemia in adults. Br J Haematol 181(1):27–37

    Article  Google Scholar 

  27. DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7–17

    Article  CAS  Google Scholar 

  28. DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617–629

    Article  CAS  Google Scholar 

  29. DiNardo CD, Rausch CR, Benton C et al (2018) Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93(3):401–407

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Penn State Cancer Institute, 500 University Dr., Hershey, PA, 17033, USA

    Neal Shah, Kevin Rakszawski, Myles Nickolich, Christopher Ehmann, Baldeep Wirk, Seema Naik, Witold Rybka, Hong Zheng, Joseph Mierski, Brooke Silar, Gina Mackey, David Claxton, Shin Mineishi & Kentaro Minagawa

  2. Penn State Children’s Hospital, 500 University Dr., Hershey, PA, 17033, USA

    Robert Greiner & Valerie Brown

Authors
  1. Neal Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin Rakszawski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Myles Nickolich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christopher Ehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Baldeep Wirk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seema Naik
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Witold Rybka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hong Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Joseph Mierski
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Brooke Silar
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Gina Mackey
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Robert Greiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Valerie Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. David Claxton
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Shin Mineishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Kentaro Minagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kentaro Minagawa.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shah, N., Rakszawski, K., Nickolich, M. et al. Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion. Ann Hematol 100, 2585–2592 (2021). https://doi.org/10.1007/s00277-021-04616-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04616-7

Keywords

Search

Navigation